Latest News

North Sea Therapeutics raises US$40m in Series B

Steatohepatitis © Nephron/commons.wikimedia.org/w/index.php?curid=7747223


by tg

NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.

Besides the completion of the ongoing Phase 2b ICONA study on icosabutate in safety and efficacy in NASH (Non-alcoholic Steatohepatitis), North Sea Therapeutics announced to push the development of two additional SEFA (Structural Engineered Fatty Acids) programmes into clinical development.

While new US investor venBio Partners led the Series B financing, and were joined by Sofinnova Investments, existing investors, Novo Seeds, Forbion, New Science Ventures (NSV) and BioGeneration Ventures (BGV) also participated in the round.

Icosabutate is a structurally enhanced omega-3 fatty acid molecule, which was originally tested to lower triglyceride levels but also showed a reduction in hepatic oxidative stress, according to Naarden-based North Sea Therapeutics.

Polyphor AG bags funding for murepavadin

Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

ADC company Araris Biotech raises CHF15.2m

Besides Pureos Bioventures, London-based 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq cofinanced the CHF12.7m addition to...

Evotec expanding at Milton Park campus

According to Evotec, adding a new building by the end of the year, will bring together all the key functions for small molecule discovery and up to...

Siemens launches COVID-19 antigen lateral flow test

As testing capacities for the SARS-CoV-2 gold standard RT-PCR are going to be exhausted upon the looming second wave of infections with the novel...

Protein Brewery raise €22m in Series A

The Series A investment round, which brings the total amount invested into the Dutch food and feed maker to €26m, was led by Novo Holdings. New...

Biotech companies launch Biotech Austria

According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...

Pfizer/BioNTech sign vaccine contract with EC

The deal includes an option for the European Commission to request an additional 100 million doses of BNT-162-b2. That's the largest initial order of...